Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 10/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 10/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | BCL2 | P10415 | 2/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4957519 | 0.94 | ALDH1A1 (0.47) | KEAP1NFE2L2ALDH1A1PTPN1CA12 | |
| SCHEMBL3920448 | 0.86 | KEAP1 (0.44) | KEAP1NFE2L2ALDH1A1PTPN1CA12 | |
| SCHEMBL4309433 | 0.84 | ALDH1A1 (0.41) | KEAP1NFE2L2ALDH1A1PTPN1CA12 | |
| SCHEMBL646518 | 0.83 | ALDH1A1 (0.54) | KEAP1NFE2L2ALDH1A1PTPN1PTPN2 | |
| SCHEMBL646673 | 0.83 | CA12 (0.43) | KEAP1NFE2L2ALDH1A1CA12CA1 | |
| SCHEMBL2893397 | 0.81 | ALDH1A1 (0.44) | KEAP1NFE2L2ALDH1A1PTPN1CA12 | |
| SCHEMBL2889117 | 0.80 | ALDH1A1 (0.45) | KEAP1NFE2L2ALDH1A1PTPN1CA12 | |
| SCHEMBL28578328 | 0.80 | ALDH1A1 (0.40) | KEAP1NFE2L2ALDH1A1PTPN1CA12 | |
| SCHEMBL1731086 | 0.80 | GAA (0.46) | KEAP1NFE2L2ALDH1A1CA12CA1 | |
| SCHEMBL29626447 | 0.80 | ALDH1A1 (0.43) | KEAP1NFE2L2ALDH1A1PTPN1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963294-B1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | NOVARTIS AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| US-8119666-B2 | 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase) | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | disclosed |
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | PTPRS, PTPN5, PTPRR | KEAP1 1827/4885NFE2L2 1890/4885ALDH1A1 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.